FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
Full approval will depend on verification of clinical benefit in a confirmatory trial
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Subscribe To Our Newsletter & Stay Updated